Specific priorities include: (1) mechanistic studies of CTLA-4+ non-regulatory T cells in cHL and their interaction with CD86+ HRS cells; (2) investigation of LAG-3 and TIGIT co-expression patterns on tumor-infiltrating lymphocytes and their sequential or simultaneous targeting strategies; and (3) detailed characterization of the CD47-SIRPα axis in cHL macrophage biology and its modulation by metabolic interventions. The gene discussed is CD86; the disease is neoplasm.